In a report released yesterday, Annabel Samimy from Stifel Nicolaus reiterated a Buy rating on Horizon Pharma Inc (NASDAQ: HZNP), with a price target of $25. The company’s shares closed yesterday at $20.12, close to its 52-week high of $20.25.
According to TipRanks.com, Samimy is a 4-star analyst with an average return of 10.6% and a 53.1% success rate. Samimy covers the Healthcare sector, focusing on stocks such as Supernus Pharmaceuticals, Jazz Pharmaceuticals, and Endo International.
Horizon Pharma Inc has an analyst consensus of Strong Buy, with a price target consensus of $22.29, representing a 10.8% upside. In a report released yesterday, Cantor Fitzgerald also maintained a Buy rating on the stock with a $21 price target.
.
See today’s analyst top recommended stocks >>
Based on Horizon Pharma Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $32.84 million. In comparison, last year the company had a GAAP net loss of $210 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Horizon Pharma Plc engages in the research, development and market of pharmaceutical products. The medicines intend to treat arthritis, inflammation and orphan diseases. It distributes its products under the brands such as Actimmune, Buphenyl, Duexis, Krystexxa, Migergot, Pennsaid, Ravicti, Rayos and Vimovo.
